Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 13Neoplasm Metastasis 9Stomach Neoplasms 5Endometrial Neoplasms 4Pancreatic Neoplasms 3Ovarian Neoplasms 3Adenocarcinoma 3Salivary Gland Neoplasms 2Prostatic Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1Neoplasms 1Neoplasm, Residual 1Mouth Neoplasms 1Melanoma 1

Interventions

Oxaliplatin 8Fluorouracil 8pembrolizumab 7Paclitaxel 6Trastuzumab 5Leucovorin 5Capecitabine 5Specimen Handling 4Radiation 4Cisplatin 4Carboplatin 4tislelizumab 3patritumab deruxtecan 3Taxes 3Radiotherapy 3Nivolumab 3ulixertinib 2trastuzumab deruxtecan 2trastuzumab biosimilar HLX02 2durvalumab 2Surgical Procedures, Operative 2Ramucirumab 2Pemetrexed 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Irinotecan 2Immunotherapy 2Exercise 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × trastuzumab deruxtecan × 30 days × Clear all
NCT07124000 2026-06-01

DP-04

AstraZeneca

Recruiting
100 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Adenocarcinoma, Anus Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Melanoma, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Urethral Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT04379596 2026-05-13

DG-03

AstraZeneca

Phase 2 Recruiting
450 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡